In January 2026, the Company and Hanmi amended the Amended Facility Agreement whereby the availability period for advances provided pursuant to the agreement was extended from December 31, 2025 to January 31, 2026. All other terms and conditions of the Amended Facility Agreement remained in full force and effect.

On January 22, 2026, the Company received the final advance from Hanmi under the Amended Facility Agreement in the amount of $1.9 million resulting in a total of $11.9 million of advances under the Amended Facility Agreement.

On February 23, 2026, the Company and Hanmi entered into the Second Amended Facility Agreement, pursuant to which Hanmi provided an additional uncommitted facility for up to $11.1 million, administered through multiple advances for the purpose of the continued clinical development of tuspetinib and to fund operations of the Company. Advances under the Second Amended Facility Agreement may be provided in one or more (but no more than six advances) until May 31, 2026. No single advance shall be for an amount in excess of $2.0 million or for an amount that is less than $0.5 million. Additionally, Hanmi may cancel availability under the Second Amended Facility Agreement at any time without notice, acting solely at its discretion. Unpaid principal with respect to each advance shall accrue interest at a rate of 6% per annum. Amounts outstanding pursuant to the Second Amended Facility Agreement, including accrued and unpaid interest, are repayable in full on August 31, 2028.

On February 23, 2026, the Arrangement Agreement was amended and restated to among other things, extend the outside date for completing the Arrangement from March 15, 2026 to June 30, 2026. On March 31, 2026, shareholders of the Company approved the Arrangement at a special meeting of shareholders held for such purpose. In connection with the Arrangement, the Company will continue from the Canada Business Corporations Act to the Business Corporations Act (Alberta). The Arrangement is expected to close in the first half of 2026, subject to the satisfaction of customary closing conditions.

In February 2026, the Company entered into a letter of intent to lease new office space in San Diego, California. The lease is expected to commence in June 2026 for a term of 48 months. The lease payment is approximately $28,000 per month, with an annual escalation of 3% per year.

On March 3, 2026 and March 27, 2026, the Company received advances of $2.0 million on each of these dates from Hanmi under the Second Amended Facility Agreement resulting in a total of $4.0 million advances to date.